NOVO-DIPIRADOL TAB 50MG TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
27-10-2006
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
DIPYRIDAMOLE
Tilgængelig fra:
NOVOPHARM LIMITED
ATC-kode:
B01AC07
INN (International Name):
DIPYRIDAMOLE
Dosering:
50MG
Lægemiddelform:
TABLET
Sammensætning:
DIPYRIDAMOLE 50MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100/1000
Recept type:
Prescription
Terapeutisk område:
MISCELLANEOUS VASODILATATING AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0106621002; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2005-08-10
Produktets egenskaber
PRODUCT MONOGRAPH
Pr
NOVO-DIPIRADOL (dipyridamole) 25, 50, 75, 100 mg Tablets
Pr
DIPYRIDAMOLE FOR INJECTION (dipyridamole) 5 mg/mL, USP
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Novopharm Limited
Date of Preparation:
30 Novopharm Court
October 26, 2006
Toronto, Ontario
M1B 2K9
Control No. 107491
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
8
DOSAGE AND
ADMINISTRATION.......................................................................................
9
OVERDOSAGE
.........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 10
STORAGE AND
STABILITY.................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
13
PHARMACEUTICAL
INFORMATION.........................................................
Læs hele dokumentet
